Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.42 |
| ▸ | DRD1 known ✓ | P21728 | 4/20 | 0.42 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.42 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.42 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.42 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.42 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.42 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.42 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.42 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.42 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.42 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.42 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.42 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.42 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.42 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.42 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15490389 | 0.99 | DRD2 (0.43) | DRD2DRD1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL4840025 | 0.83 | DRD1 (0.40) | DRD2DRD1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL4841102 | 0.83 | CHRM1 (0.40) | DRD2DRD1CHRM2CHRM4CHRM5 | |
| SCHEMBL14156630 | 0.82 | DRD1 (0.41) | DRD2DRD1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL937256 | 0.81 | DRD2 (0.57) | DRD2DRD1CHRM2CHRM4CHRM5 | |
| SCHEMBL21011831 | 0.78 | DRD2 (0.39) | DRD2DRD1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL4835718 | 0.77 | CHRM2 (0.37) | DRD2DRD1CHRM2CHRM4CHRM5 | |
| SCHEMBL14156632 | 0.76 | CHRM2 (0.38) | DRD2DRD1CHRM2CHRM4CHRM5 | |
| SCHEMBL15485320 | 0.76 | CHRM1 (0.72) | DRD2DRD1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL4839524 | 0.75 | CHRM2 (0.40) | DRD2DRD1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3581195-B1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| EP-3492473-B1 | HAPTENS OF OLANZAPINE | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-30 | — | — | EP | disclosed |
| US-11226345-B2 | Antibodies to olanzapine haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| US-10712353-B2 | Antibodies to olanzapine haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-14 | — | — | US | disclosed |
| EP-3492473-A1 | HAPTENS OF OLANZIPINE | Janssen Pharmaceutica NV (BE) | 2019-06-05 | — | — | EP | disclosed |
| EP-2887952-B1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-15 | — | — | EP | disclosed |
| EP-2888269-B1 | HAPTENS OF OLANZAPINE | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-24 | — | — | EP | disclosed |
| US-20170343569-A1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-30 | — | — | US | disclosed |
| US-20170240653-A1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-24 | — | — | US | disclosed |
| US-9303041-B2 | Haptens of olanzapine | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-05 | — | — | US | disclosed |
| EP-2887952-A1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | ORTHO-CLINICAL DIAGNOSTICS, INC. (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20140213766-A1 | HAPTENS OF OLANZIPINE | ORTHO-CLINICAL DIAGNOSTICS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140057303-A1 | Antibodies to Olanzapine Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031656-A1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | ORTHO-CLINICAL DIAGNOSTICS, INC (US) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11226345-B2 | Antibodies to olanzapine haptens and use thereof | HTR4, HTR3C, HTR1A | DRD2 65/4885DRD1 166/4885CHRM2 450/4885 |
| US-10712353-B2 | Antibodies to olanzapine haptens and use thereof | HTR4, HTR3C, HTR1A | DRD2 65/4885DRD1 166/4885CHRM2 450/4885 |
| US-20140213766-A1 | HAPTENS OF OLANZIPINE | OPRL1, ADRA1D, CHRNA2 | DRD2 16/4885DRD1 36/4885CHRM2 28/4885 |
| US-20140057303-A1 | Antibodies to Olanzapine Haptens and Use Thereof | HTR4, HTR3C, HTR1A | DRD2 65/4885DRD1 166/4885CHRM2 450/4885 |
| US-20170240653-A1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | HTR4, HTR3C, HTR1A | DRD2 65/4885DRD1 166/4885CHRM2 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.